New option for proteinuric CKD now on the PBS

For optimum impact, the agent needs to be initiated early while kidney function is relatively preserved, a specialist says
Professor Carol Pollock
Professor Carol Pollock.

The first new treatment in more than 20 years for chronic kidney disease — the SGLT2 inhibitor dapagliflozin — is now government subsidised for patients with or without diabetes.

The PBS listing on 1 September comes 12 months after the TGA approved the drug for use in adults with chronic kidney disease (CKD) stage 2-4 and a urinary albumin-to-creatinine ratio of at least 30mg/g.